{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:23:34Z","timestamp":1774437814110,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13256-018-1727-7","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T09:24:37Z","timestamp":1529573077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9934-4564","authenticated-orcid":false,"given":"Yinan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,1]]},"reference":[{"key":"1727_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9:425\u201337.","journal-title":"Lancet Neurol"},{"key":"1727_CR2","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/14740338.2017.1346082","volume":"16","author":"M Clerico","year":"2017","unstructured":"Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis. Expert Opin Drug Saf. 2017;16:963\u201372.","journal-title":"Expert Opin Drug Saf"},{"key":"1727_CR3","first-page":"597","volume":"17","author":"K Garrels","year":"1996","unstructured":"Garrels K, Kucharczyk W, Wortzman G, Shandling M. Progressive multifocal leukoencephalopathy: clinical and MR response to treatment. AJNR Am J Neuroradiol. 1996;17:597\u2013600.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1727_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1742-6405-6-16","volume":"6","author":"DM Murdoch","year":"2009","unstructured":"Murdoch DM, Suchard MS, Venter WD, Mhlangu P, Ottinger JS, Feldman C, Van Rie A, Glencross DK, Stevens WS, Weinhold KJ. Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS). AIDS Res Ther. 2009;6:16.","journal-title":"AIDS Res Ther"},{"key":"1727_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1212\/WNL.0000000000003740","volume":"88","author":"D Landi","year":"2017","unstructured":"Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D, Italian PML study group. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017;88:1144\u201352.","journal-title":"Neurology"},{"key":"1727_CR6","first-page":"809252","volume":"2015","author":"JM Honce","year":"2015","unstructured":"Honce JM, Nagae L, Nyberg E. Neuroimaging of Natalizumab complications in multiple sclerosis: PML and other associated entities. Mult Scler Int. 2015;2015:809252.","journal-title":"Mult Scler Int"},{"key":"1727_CR7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/acn3.114","volume":"1","author":"T Dong-Si","year":"2014","unstructured":"Dong-Si T, Richman S, Wattjes MP, Wenten M, Gheuens S, Philip J, Datta S, McIninch J, Bozic C, Bloomgren G, Richert N. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol. 2014;1:755\u201364.","journal-title":"Ann Clin Transl Neurol"},{"key":"1727_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1212\/WNL.0b013e318246d6d8","volume":"78","author":"NF Blair","year":"2012","unstructured":"Blair NF, Brew BJ, Halpern JP. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology. 2012;78:507\u20138.","journal-title":"Neurology"},{"key":"1727_CR9","first-page":"637","volume":"21","author":"T Dong-Si","year":"2015","unstructured":"Dong-Si T, Gheuens S, Gangadharan A, Wenten M, Philip J, McIninch J, Datta S, Richert N, Bozic C, Bloomgren G, Richman S, Weber T, Clifford DB. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neuro-Oncol. 2015;21:637\u201344.","journal-title":"J Neuro-Oncol"},{"key":"1727_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/jnnp-2016-315106.113","volume":"87","author":"C McGuigan","year":"2016","unstructured":"McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87:117\u201325.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1727_CR11","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870\u201380.","journal-title":"N Engl J Med"},{"key":"1727_CR12","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1177\/1352458513481010","volume":"19","author":"M Blinkenberg","year":"2013","unstructured":"Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sorensen PS. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab. Mult Scler. 2013;19:1226\u20139.","journal-title":"Mult Scler"},{"key":"1727_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jocn.2015.08.027","volume":"25","author":"MJ Fabis-Pedrini","year":"2016","unstructured":"Fabis-Pedrini MJ, Xu W, Burton J, Carroll WM, Kermode AG. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment. J Clin Neurosci. 2016;25:145\u20137.","journal-title":"J Clin Neurosci"},{"key":"1727_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00415-012-6759-0","volume":"260","author":"EM Mc Govern","year":"2013","unstructured":"Mc Govern EM, Hennessy MJ. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab. J Neurol. 2013;260:665\u20137.","journal-title":"J Neurol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1727-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-018-1727-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1727-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T21:06:27Z","timestamp":1561928787000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-018-1727-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1727"],"URL":"https:\/\/doi.org\/10.1186\/s13256-018-1727-7","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,1]]},"assertion":[{"value":"17 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This case report was approved by the internal research ethics committee of University of Texas Southwestern Medical Center in accordance with the code of ethics of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yinan Zhang has no conflict of interests to declare. Crystal Wright is a speaker for Genzyme and Novartis and is involved in a clinical trial with MED Day. Angela Flores is a speaker and consultant for Biogen and Genentech. The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"187"}}